PRF1 and cancer: The observed association between AHNAK2 and these immune cell types may provide new insights into the immunomodulatory mechanisms of AHNAK2 in the context of cancer.[56] Tregs can secrete inhibitory cytokines, including IL-10, TGF-β, and IL-35, and can also kill effector cells through granzyme and perforin.[57,58] It has also been reported[59] that Tregs compete with effector T cells to deplete IL-2, thereby inhibiting the growth of effector T cells.